Koninklijke Philips N.v Stock Earnings Reports

Philips reported Q2 2026 results broadly in line with expectations. Comparable sales grew ~4% led by all segments, with order intake resilient (rolling 12-month order intake +5%) though Q2 orders were down 1% due to timing of several large Monitoring orders that shifted into Q3. Adjusted EBITA margin improved to 16.4% including a U.S. tariff refund; management says the underlying margin excluding the refund was 12.2% in Q2 and they reiterate a full-year underlying adjusted EBITA margin target of 12.5%–13% (13.5%–14% including the tariff refund). Free cash flow in Q2 was €222m (including the refund); full-year reported free cash flow outlook raised to €1.5–1.7bn (underlying €1.3–1.5bn excl. refund). Key drivers: strong North America and Europe demand (notably Image-Guided Therapy and Monitoring wins), ongoing momentum in Personal Health (new Sonicare and other product launches and retail expansion), continued progress on innovation and regulatory clearances, and productivity savings (€132m in Q2; €258m YTD toward a €1.5bn three-year target). Headwinds: higher tariffs, elevated cost inflation (high single-digit view for 2026), FX effects and China centralized procurement pressure on some health-systems businesses. Management expects Q3 sales near the lower end of the full-year range (phasing effects from China and Ultrasound) and a sequential margin dip in Q3 with a meaningful step-up in Q4; they remain confident in the full-year outlook and longer-term CMD ambitions (mid-single-digit CAGR and mid-teens EBITA margin by 2028).